Clinical Trial Update: Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age [Phase 2]

View source ↗

Summary

Phase 2 trial results update for GSK's malaria vaccine candidate SB257049, evaluating efficacy, safety and immunogenicity with schedules including fractional do…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• SB257049

Snippet

Sponsor: GlaxoSmithKline | Conditions: Malaria | Phase 2 | Status: COMPLETED | Results posted: 2024-05-21